Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J’s Tremfya shows promise in psoriatic arthritis patients who are TNFi non-responders

By Brian Buntz | June 2, 2021

Janssen Johnson & Johnson pharmaceuticalsThe Janssen division of Johnson & Johnson (NYSE:JNJ) has announced that its selective IL-23 inhibitor Tremfya (guselkumab) led to joint symptom improvement and skin clearance in the majority of patients with an inadequate response to tumor necrosis factor inhibitors (TNFi’s).

After 24 weeks of treatment, 44.4% of patients who received Tremfya had at least a 20% improvement in joint symptoms using the American College of Rheumatology’s ACR20 scale, which requires at least a 20% improvement in several arthritis measures. Some 19.9% of placebo recipients had the same degree of improvement.

At one year, 57.7% achieved more than 20% improvement in joint symptoms using the American College of Rheumatology’s ACR20 scale, which requires at least a 20% improvement in several arthritis measures. Some 53.4% of the psoriatic arthritis patients had complete skin clearance.

“We’re basically continuing to develop the body of evidence to help physicians make decisions about how best to use Tremfya,” said Dr. Alyssa Johnsen, VP and rheumatology disease area leader at Janssen.

Tremfya is currently FDA-indicated for moderate-to-severe plaque psoriasis patients eligible for systemic therapy and patients with active psoriatic arthritis.

Janssen's Tremfya

Tremfya (guselkumab) won FDA approval for adult patients with active psoriatic arthritis in 2020.

The recent COSMOS Phase 3b study is unique in its focus on TNFi non-responders, Johnsen said. “While the DISCOVER [1 and 2] studies studied patients who had been on TNF inhibitors in the past, COSMOS is a dedicated study specifically looking at this patient population who either had had an inadequate [TNFi] response based on efficacy or had intolerance,” Johnsen said. “This is really important because these patients have historically been harder to treat.”

While TNF inhibitors have helped transform the treatment landscape for patients with psoriasis and psoriatic arthritis, “there still are patients who just don’t achieve sufficient responses,” Johnsen said. “And it’s really important for physicians to understand how a new mechanism of action can actually work in this harder-to-treat population.”

A related challenge involves managing symptoms of psoriatic arthritis patients who have a loss of response to TNF blockers over time.

Psoriatic arthritis is a chronic inflammatory disease that can significantly impact patients’ quality of life. At EULAR’s European Congress of Rheumatology 2021, Janssen shared data indicating that active psoriatic arthritis frequently leads to loss of work productivity while negatively affecting activity outside of work.

In the separate DISCOVER 2 trial, psoriasis patients receiving Tremfya demonstrated significant improvements in anxiety, depression, fatigue and other measures.

But the positive data from the COSMOS study and other studies related to psoriasis and psoriatic arthritis could lead to continued improvements for many of these patients, Johnsen said. “As physicians get better at treating [psoriasis] patients, the bar gets higher for patients and even what patients would expect for themselves,” she said. “The ultimate goal, I think, for everyone, is ultimately remission, and that’s a very high bar.”

Biologics such as Tremfya have already had a considerable impact on the treatment of psoriasis. TNF inhibitors have “made a dramatic difference in patients’ lives — to have something that could provide a meaningful change in their joint symptoms, swelling and in their progression to joint damage,” Johnsen said. “And there also have been significant benefits with respect to skin disease.”


Filed Under: clinical trials, Drug Discovery, Rheumatology
Tagged With: COSMOS study, guselkumab, Janssen, psoriatic arthritis., TNFi's, Tremfya, tumor necrosis factor inhibitors
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE